September 21, 2021, Palo Alto, California – Koji Tanabe, Founder and CEO of I Peace, Inc., has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021”. [Read more…]
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
A novel animal component-free medium that supports robust expansion and maintenance of human pluripotent stem cells.
Minneapolis, September 14, 2021 — Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne’s comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characterization. [Read more…]
JW Therapeutics Achieves Approval of Sixth CAR-T Product Globally by NMPA in China
The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities
Cord Blood Bank Cryoviva Singapore Continues Geographic Expansion with Entry into Bahrian
Singapore, Sep 7, 2021 – Local family cord blood bank Cryoviva Singapore is continuing with its rapid geographic growth plans with an entry into the Bahrain market. This latest new market entry closely follows Cryoviva establishing a footprint in Dubai to serve couples in the UAE that are on the family way. [Read more…]
Treefrog Therapeutics Secures $75M in Series B Financing To Advance a Pipeline of Stem Cell-Derived Cell Therapies and Deploy Proprietary C-Stem™ Technology in the USA & Japan
Frederic Desdouits, PhD, named chief executive officer. Co-founder Kevin Alessandri, PhD, relocates to Boston to drive TreeFrog Therapeutics’ expansion in the U.S.
Bordeaux, France/September 13th, 2021 – TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M). [Read more…]
